Pay in 4 interest-free payments of $5.18 Learn more
Ships within 48 hours · Estimated delivery Sep 15 - Sep 20
gaining weight on compounded semaglutide Why Am I Tirzepatide? Medical Causes Explained Healthy weight management New GLP-1 alternative, eloralintide, Flavor:Pina Colada
New GLP-1 alternative, eloralintide, leads to 20% weight loss in trial
GLP-1s May Help With Increased appetite related to metabolic imbalance Ongoing cravings that interfere with healthy eating habits Difficulty losing weight despite consistent nutrition and exercise Metabolic concerns linked to insulin resistance Overeating caused by disrupted hunger and fullness signals Potential Benefits of GLP-1 Therapy Reduced hunger and better control over cravings More balanced blood sugar levels that may help stabilize energy Enhanced satiety to support portion awareness Gradual, medically supervised weight loss without stimulants Improved metabolic function that supports long-term progress A dosing plan tailored to your individual response Reduced reliance on extreme dieting or intense exercise routines Improved consistency in maintaining healthy habits Our Personalized GLP-1 Program in Stuart Initial consultation Your first visit is designed to get a complete understanding of your health
Healthy weight management
Flavor:Pina Colada
Key facts for understanding the device context: Trial structure: Four or more core trials (TRIUMPH-1 through TRIUMPH-4 plus TRIUMPH-Outcomes), enrolling 5,800 or more participants across programs Administration: Subcutaneous injection, once weekly, dose escalation to 12mg maximum TRIUMPH-4 results (December 2025): Participants on 12mg retatrutide lost an average of 28.7% body weight at 68 weeks, versus 2.1% on placebo (Giblin et al., PMID 41090431) Phase 2 comparison: 24.2% body weight loss at 48 weeks on 12mg (Jastreboff et al., NEJM 2023) - a different trial, shorter duration, earlier data TRIUMPH-Outcomes: Active Phase 3 trial (NCT06383390), estimated 10,000 participants, completion February 2029 - investigating cardiovascular outcomes What the Phase 3 Device Disclosure Gap Means Eli Lilly has not disclosed pen device specifications for retatrutide because the drug is not yet approved, and device details are part of the commercial product launch package
